A B S T R A C T Our studies demonstrated that phenoxybenzamine, 10 mg/kg, administered intravenously to intact anesthetized dogs, produced an immediate and significant increase of heart rate and cardiac output. In heart-lung preparations, phenoxybenzamine had no effect or a negative cardiac inotropic effect, hence these actions were not related to direct cardiac action or to release of myocardial norepinephrine stores. Serial estimations of arterial blood catecholamines after phenoxybenzamine showed an increase of epinephrine and norepinephrine; the peak values of these catecholamines did not correlate well with the maximum cardiac output responses. Ganglionic blockade largely eliminated the early cardiac effects of phenoxybenzamine, hence its action did not appear to be upon peripheral terminals of postganglionic sympathetic or parasympathetic nerves.
A B S T R A C T Our studies demonstrated that phenoxybenzamine, 10 mg/kg, administered intravenously to intact anesthetized dogs, produced an immediate and significant increase of heart rate and cardiac output. In heart-lung preparations, phenoxybenzamine had no effect or a negative cardiac inotropic effect, hence these actions were not related to direct cardiac action or to release of myocardial norepinephrine stores. Serial estimations of arterial blood catecholamines after phenoxybenzamine showed an increase of epinephrine and norepinephrine; the peak values of these catecholamines did not correlate well with the maximum cardiac output responses. Ganglionic blockade largely eliminated the early cardiac effects of phenoxybenzamine, hence its action did not appear to be upon peripheral terminals of postganglionic sympathetic or parasympathetic nerves.
Phenoxybenzamine was found to have antivagal actions which might account for some of the delayed cardiac acceleration. When beta adrenergic receptor blockade was induced by sotalol, the cardiac effects of phenoxybenzamine were largely eliminated. Baroreceptor denervation prevented the increase of cardiac output after phenoxybenzamine. These observations are consistent with the concept that the increase of cardiac rate and output produced by phenoxybenzamine is principally mediated by baroreceptor reflexes acting through sympathetic cardiac nerves or circulating catecholamines.
INTRODUCTION
Phenoxybenzamine, an alpha adrenergic receptor blocking agent, is known to increase the cardiac output and stroke volume (1) and renal blood flow (2) when given intravenously to dogs with experimental shock. In a recent study, we found that intravenous phenoxybenzaReceived for publication 26 March 1970 and in revised form 30 June 1970. mine increased the cardiac stroke volume, heart rate, and cardiac output of dogs during experimental cardiac tamponade (3). Aviado (4) stated that alpha receptor blocking drugs induce cardiac stimulation mostly because the fall in systemic blood pressure accompanying systemic vasodilation initiates reflex tachycardia. However, no studies of intact animals were described. Nickerson found that the myocardial effects of direct or reflex sympathetic nerve stimulation were not inhibited by dibenamine and other alpha adrenergic blocking atents (5) . Nickerson stated that phenoxybenzamine commonly produces a moderate increase in cardiac output and a decrease in total peripheral resistance in normal recumbent subjects, but no data were presented (6) .
In the only published study of the cardiac output of intact animals that we have been able to find, Mills and Moyer reported a decrease in cardiac output of dogs given phenoxybenzamine, 10 mg/kg intravenously (7) . Since these results appeared to conflict with the observations cited above, we decided to investigate the hemodynamic effects of phenoxybenzamine in the intact anesthetized animal. The studies to be described showed that phenoxybenzamine did increase the cardiac output in intact dogs. The mechanism of this response was then examined in animals undergoing ganglionic blockade, in animals during beta adrenergic receptor blockade, and in the dog heart-lung preparation in which presumably neither central nor ganglionic sympathetic activity is present. Blood catecholamine levels were measured in some experiments and vagal nerve stimulation frequency-response curve were evaluated in others. Some animals were studied after baroreceptor denervation.
METHODS
Dogs were studied under morphine-chloralose anesthesia. The animals each weighed approximately 20 kg, and each received heparin, 5000 U intravenously. The animals were anesthetized with morphine, 3 always above 95%o of capacity, and rectal temperature varied no more than 10C. In group I, systemic arterial oxygen saturation was no lower than 89%o of capacity; arterial blood pH was between 7.34 and 7.45; rectal temperatures were not measured in this group. In group VII systemic arterial oxygen saturation was no lower than 85%o of capacity; arterial blood pH and rectal temperatures were controlled as in groups II through VI. Seven groups of animals were studied.
Group I. (a) The hemodynamic effects of phenoxybenzamine, 10 mg/kg intravenously, were investigated in eight dogs. Norepinephrine, 1 or 5 ,g/kg, was administered as an intravenous bolus before phenoxybenzamine and at the end of the experiment to evaluate the efficacy of alpha blockade in preventing arterial blood pressure rise. Phenoxybenzamine was given at a rate of 2 mg/kg per min over a period of 5 min. Hemodynamic measurements were made in a control period before phenoxybenzamine, immediately after phenoxybenzamine, and 10 min after phenoxybenzamine.
(b) The hemodynamic effects of phenoxybenzamine, 5 mg/kg, given intravenously in 5 min were studied in six open chest dogs. In these animals, respirations were supported by a Harvard respirator which employed 100% oxygen. In addition to systemic blood and cardiac output, left atrial mean pressure was measured as an estimate of left ventricular filling pressure.
Group II. Arterial plasma catecholamines were measured in four additional animals. The animals were prepared and investigated as in group I, except that arterial plasma catecholamines were measured in six periods. There were two control periods; the third period was selected during the phenoxybenzamine injection as soon as a positive chronotropic effect was observed. The fourth period was immediately after completion of the phenoxybenzamine administration. The fifth and sixth periods were selected from the following three: the 5-, 10-, and 30-min periods after phenoxybenzamine. The blood sample from the period showing the least rise in cardiac output was discarded and catecholamine analysis was performed upon the remaining two. Because of the large volume of blood required for the catecholamine studies (20 ml for each sample) (8, 9) , the blood removed from the experimental animal was replaced with matched donor dog's blood.
Group III. The hemodynamic effects of phenoxybenzamine were studied in six animals after sotalol (MJ-1999)-induced beta adrenergic blockade. The animals were investigated as in group I, except that beta adrenergic blockade was induced by sotalol,' 5 mg/kg intravenously. The efficacy of beta blockade was evaluated by the heart rate response to isoproterenol, 0.5 Ag/kg intravenously given before sotalol, 5 min after sotalol, and at the end of the experiments. 5 min after sotalol, the heart rate increase with isoproterenol was either completely blocked or rose at most 3% of the increase before sotalol. At the end of the experiments, the heart rate response to isoproterenol was found to be blocked by 98, 93, 92, 92, 91, and 78% when compared to the rate increase before sotalol in the six respective animals.
Group IV. The hemodynamic effects of phenoxybenzamine were evaluated in six animals after autonomic ganglionic blockade. The animals were prepared as in group I. Ganglionic blockade was induced with hexamethonium, 10 mg/kg intravenously followed by atropine, 1 mg/kg intravenously (10) . The efficacy of hexamethonium-induced ganglionic blockade was tested by observing the heart rate response to stimulation of the peripheral end of the sectioned right vagus nerve in the neck before hexamethonium and then after hexamethoniurn but before atropine was given. The ganglionic blockade was effective in all animals as judged by the complete prevention of the negative chronotropic effect of vagal stimulation in each animal. The left vagus was sectioned before stimulating the right vagus. The right vagus was stimulated with l-msec impulses at supramaximal voltage with frequencies of 1, 3, and 10 cycles/sec by means of a Grass S-4 stimulator (Grass Instrument Co., Quincy, Mass.).
Group V. The vagal effects of phenoxybenzamine were studied in six animals that received the drug and in three control animals. The animals were prepared as in group I. The peripheral end of the right vagus nerve was stimulated at supramaximal voltage with 1-msec stimuli and at 1, 3, 10, and 30 cycles/sec. The heart rate response was evaluated with an electrocardiogram so that the atrial rate might be determined. The order of application of stimulus frequency was randomized. The frequency-response curve was determined before and after phenoxybenzamine, 10 mg/kg intravenously. The control animals received only the vehicle, which consisted of 3 ml of absolute alcohol and 47 ml of physiologic saline.
(b) In five dogs, the effects of peripheral right vagal nerve stimulation were similarly examined in three periods; control, during cardiac acceleration produced by intravenous isoproterenol infusion, 3 Blood temperature, measured from the right atrium, was controlled between 36.80 and 39'C by a heatedjacket blood reservoir, except in one animal, in which the temperature range was 35.40-36.2'C. Blood pH was controlled between 7.35 and 7.45. Arterial oxygen saturation was always above 95% of capacity. The phenoxybenzamine was dissolved in a vehicle of 3 ml of absolute ethanol and 47 ml of physiologic saline for 5 mg/kg doses and in 0.6 ml of alcohol and 49.4 ml of saline for 1 mg/kg doses. In two animals, 1 mg/kg of phenoxybenzamine was given. In four animals, a total of 5 mg/kg of phenoxybenzamine was given in divided doses of 1 mg/kg at intervals of 2 min. Cardiac outputs and pressures were determined after each dose. In each experiment the effect of the vehicle was also tested in like manner. The vehicle preceded the phenoxybenzamine in half the experiments and followed it in the others.
Group VII. The hemodynamic effects of phenoxybenzamine, 10 mg/kg intravenously, were evaluated in five dogs after baroreceptor denervation. The animals were given morphine chloralose anesthesia, and respiration was maintained by a Harvard respirator and ambient air. Cardiac outputs, arterial blood pressure, and heart rates were measured in a Table I . The average heart rates in the two control periods were 82.9 ±+11.2 (s.E.), and 87.8 ±11.2 beats/min ( Fig. 1 ). Immediately after phenoxybenzamine, the average heart rate was 196.5 ±18.9 beats/min, P < 0.001. 10 min after phenoxybenzamine, the average heart rate was 189.8 ±21.4 beats/min, P < A Ganglionic Blockade a Sotalol * Control 10 Minutes After PhenoxyBenzamine FIGURE 1 Effect of phenoxybenzamine, 10 mg/kg intravenously upon heart rate in the following three groups of animals: controls; animals with beta adrenergic receptor blockade. The centers of the vertical bars represent means; the termini of these bars represent the limit of 1 SE from the mean. Norepinephrine, 5 mg/kg intravenously, was given between the first and second control measurements to establish a base line for the later demonstration of effective alpha adrenergic blockade. The effects of norepinephrine upon heart rate and blood pressure subsided within [3] [4] [5] Fig. 2 ). Immediately after phenoxybenzamine, the average cardiac output had increased to 193.4 ±13.8 ml/kg per min, P < 0.001. 10 min after phenoxybenzamine, the average cardiac output was 197. 8±24 ml/kg per min, P < 0.05. The average of right atrial pressures showed little change after phenoxybenzamine (Table I) .
(b) The hemodynamic changes produced by administration of phenoxybenzamine 5 mg/kg intravenously are summarized in Table II . The cardiac output increased significantly immediately after phenoxybenzamine and was significantly elevated 10 min after phenoxybenzamine (Table II) . The heart rate was significantly increased over the control value at the same times, and the systolic arterial pressure was significantly lower (Table II). The unexpected increase in systolic blood pres- (Fig. 3) . The group relationship between systolic arterial pressure, arterial blood epinephrine and norepinephrine levels, heart rate, and cardiac output and right atrial mean pressure is shown in Fig. 4 Fig. 1 and Table I . The average heart rate in the control period was 101 ±-9.1 beats/min. After sotalol, the mean heart rate was 92 ±5.3 beats/min, P > 0.2. Immediately after phenoxybenzamine, the average heart rate was 101 ±-5.2 beats/min, P> 0.1. 10 min after phenoxybenzamine, the average heart rate was 112 ±E6.8 beats/min, P < 0.02. The increase above the postsotalol heart rate was significant. The cardiac output responses to phenoxybenzamine after sotalol are illustrated in Fig.   2 (Table I) . The heart rate did not increase significantly immediately after phenoxybenzamine or 5 min later but did show a significant rise after ten min. The effects of phenoxybenzamine upon cardiac output after ganglionic blockade are shown in Fig. 2 and Table III. The cardiac output was significantly reduced after ganglionic blockade with no significant rise immediately after phenoxybenzamine or 5 min later. There was a significant increase of cardiac output over that immediately after ganglionic blockade 10 min after phenoxybenzamine.
Group V. (a) The percentage decrease from control in atrial rate induced by vagal stimulation carried out before and after phenoxybenzamine is shown in Table IV and in Fig. 5 . The mean heart rate was significantly greater after phenoxybenzamine, 245.5, as compared to a control rate of 182.2 beats/min, P < 0.01. The heart rate was a significantly higher percentage of the control after phenoxybenzamine at each frequency of stimulation, except at 30 cycles/second (Table IV and Fig. 5 ). In the three control animals that received only the vehicle, the heart rate was not significantly different in response to vagal stimulation when done before and after the vehicle. The vehicle consisted of 3 ml of absolute alcohol and 47 ml of physiologic saline. The absolute decreases of heart rate during vagal stimulation before and after phenoxybenzamine were compared (Table V). After phenoxybenzamine the absolute decrease was significantly less during vagal stimulation at 1 and 3 cycles/sec, but not at 10 cycles/sec. At a stimulation frequency of 30 cycles/sec the absolute decrease of heart rate was greater after phenoxybenzamine.
(b) Table VI shows the results of peripheral vagal nerve stimulation in group V b. The heart rate response, expressed as a percentage of control, was not significantly decreased when the mean heart rate was increased from 178 to 235.8 per min by isoproterenol infusion (Table   VI ). In the same animals, the mean heart rate was 249.6
per min after phenoxybenzamine. The heart rate was significantly higher than during isoproterenol with vagal stimulation at 1 and 10 cycles/sec, but not at 30 cycles/ sec. Animal No. 1625 had a heart rate after phenoxybenzamine comparable to that during isoproterenol infusion and demonstrated much less response to vagal stimulation after phenoxybenzamine (Table VI) .
Group VI. Dog heart-lung preparations. In the two preparations in which 1 mg of phenoxybenzamine per kg body weight was given, cardiac output, left atrial pressure, and left ventricular force did not change. In the four preparations in which phenoxybenzamine, 5 mg/kg, was given, negative cardiac inotropic effects were pronounced in two and slight in two. In the two animals in which the effects were slight, cardiac outputs declined from 1111 to 909 ml/min and from 1250 to 1071 ml/min, respectively. In the two animals with pronounced negative inotropic effects the cardiac outputs decreased from 909 to 294 ml/min (Fig. 6) and from 1035 to 161 ml/min after phenoxybenzamine. In each of these four animals the left ventricular force decreased, and the left atrial pressure increased after phenoxybenzamine (Fig. 6) . Administration of the vehicle had no effects upon these variables. The plienoxybenzamine had no significant effect upon heart rate in these heartlung preparations. Group VII. The hemodynamic effects of phenoxybenzamine 10 mg/kg given intravenously in dogs with baroreceptor denervation are summarized in Table VII . The hemodynamic changes produced by phenoxybenzamine in group I a intact dogs are also shown for comparison. In the five group VII animals, control cardiac outputs, systolic blood pressure, and heart rates were comparable to those in group I intact animals. After baroreceptor denervation, heart rate and systolic blood pressure rose; there was a significant increase in cardiac output. Immediately after phenoxybenzamine, the mean cardiac output did not rise in the group VII baroreceptor denervated animals (Table VII) . The cardiac output rose an average of 51% in the intact animals; the difference was significant statistically, P < 0.02. 10 min after phenoxybenzamine, the mean cardiac output increased 55.5% over control in the intact animals, but was 23.1% less than control in the baroreceptor-denervated animals. The difference was significant statistically, P <0.02. Phenoxybenzamine administration was followed by a much greater increase in heart rate in the intact animals and by a much lower arterial blood pressure in the baroreceptor-denervated animals.
DISCUSSION
Our studies showed a consistent increase of cardiac output and of heart rate in anesthetized intact dogs after phenoxybenzamine, 10 mg/kg body weight given intravenously. We considered several possible mechanisms of this action. These included a direct cardiac effect of phenoxybenzamine, liberation of catecholamines from the adrenal medulla and sympathetic nerve endings, an antivagal action, direct stimulation of the sympathetic nervous system, and a reflex effect operating through the carotid and aortic baroreceptors which were affected by the fall in blood pressure resulting from alpha adrenergic receptor blockade.
We investigated the possibility of a direct cardiac effect of phenoxybenzamine in dog heart-lung preparations. Small doses of phenoxybenzamine (1 mg/kg) had no effect or a negative inotropic effect; larger doses (5 mg/kg) had only a negative inotropic effect with no consistent chronotropic action. Hence, we concluded that the observed positive inotropic and chronotropic effects of phenoxybenzamine in intact dogs were not related to direct cardiac effects or release of myocardial norepinephrine stores. These results are analogous to those reported by Moran and Perkins (11) FIGURE 3 Graph showing lack of relation between change in cardiac output and absolute levels of arterial epinephrine and norepinephrine after phenoxybenzamine, 10 mg/kg, intravenously.
found that phenoxybenzamine 20 mg/kg intravenously increased the heart rate and right ventricular contractile force in dogs. In the perfused rabbit heart, phenoxybenzamine 5 or 10 isg/ml depressed cardiac contractility and the response to epinephrine. These observations differ from those reported by Chang (13) who found that 0.1-0.2 lAg of phenoxybenzamine had positive inotropic and chronotropic effects in the isolated perfused rat heart. These actions were prevented by reserpine pretreatment or by propranolol or MJ-1999. It was suggested that phenoxybenzamine exerted sympathomimetic effects by releasing catecholamines from the heart as shown previously (14) . The difference between Chang's observations and ours may be related to the small drug concentrations employed by him, or to a species difference. Chang did find negative inotropic effects of phenoxybenzamine in his studies when the dose was increased to 0.5 lig.
We examined the possibility that circulating epinephrine and norepinephrine released from sympathetic nerve endings and the adrenal medulla might be responsible for the increased heart rate and cardiac output after phenoxybenzamine. Benfey, Ledoux, and Melville found that phenoxybenzamine, 10 and 20' mg/kg, increased the -a 20 to 30 Minutes After Phenoxybenzamine FIGURE 4 Graph of relation between blood epinephrine and norepinephrine after phenoxybenzamine, 10 mg/kg intravenously, and cardiac output, heart rate, and systolic blood pressure in the four animals of group II. urinary output of adrenaline and noradrenaline in dogs anesthetized with phenobarbitone (15) . Willey (16) found in cats that phenoxybenzamine, 10 mg/kg, increased the vasopressor activity of splenic venous and femoral arterial plasma. Arterial blood epinephrine and norepinephrine rise after phenoxybenzamine (17) . Phenoxybenzamine interferes with the destruction of noradrenaline in the body (18) . Evidence of increased adrenal and splenic catecholamine release during nerve stimulation has been found after phenoxybenzamine (19) . Our studies confirm the increase of arterial plasma epinephrine and norepinephrine after intravenous phenoxybenzamine. The peak increase of the plasma levels of these catecholamines did not correlate with the maximum observed changes in cardiac output and heart rate. Thus it is not certain whether or not circulating catecholamines were principally responsible for the cardiac rate and output changes which were observed after phenoxybenzamine.
Sotalol (dl MJ-1999) is an effective beta sympathetic receptor blocking agent. Levy and Richards (20) used 9.4 X 10' M isoproterenol and the isolated beating rabbit atrium to study the beta adrenergic blocking effects of sotalol. The concentration required to achieve 50% inhibition of the positive inotropic effects of isoproterenol indicated that sotalol had somewhat less than one-tenth the action of dl-propranolol. However, propranolol depressed myocardial contractility; this effect was absent in equal or higher concentration of sotalol. Hence sotalol seemed a better choice than propranolol as a beta blocking agent in experiments. Sotalol has been found to block the effect of tyramine on isolated rabbit atria and thus is believed to prevent norepinephrine release (21) . In the present experiments, sotalol effectively prevented an increase in cardiac output after phenoxybenzamine. The heart rate increased only in the 10 min period after phenoxybenzamine and then did not exceed control values significantly. The effective blockade of the effects of phenoxybenzamine upon heart rate and cardiac output by sotalol is consistent with an action mediated by the sympathetic cardiac nerves or by circulating catecholamines. Such sympathetic stimulation might be effected either through reflex action or by direct stimulation of sympathetic nerve centers, ganglia, or peripheral nerves. The decrease in afterload produced by phenoxybenzamine might be expected to increase cardiac output even in the absence of effective cardiac sympathetic innervation. However this anticipated increase of cardiac output might not occur if venous return were decreased or if the heart were depressed by impaired coronary flow or by sotalol or phenoxybenzamine. Venomotion depends upon both alpha and beta adrenergic receptors (22) . Thus the administration of both phenoxybenzamine, an alpha adrenergic blocking agent. and sotalol, a beta adrenergic blocking agent, might be expected to impair venous return to the heart, thus limiting the cardiac output response. Phenoxybenzamine alone, since it affects only alpha adrenergic receptors, woud not be expected to impair cardiac venous return to the same degree. Right atrial pressures were essentially unchanged after phenoxybenzamine in both our control animals and in those with beta adrenergic blockade. Hence we had no clear evidence of either cardiac depression or impaired venous return. 1582  180  40  72  140  180  246  14  50  106  182  1584  180  56  96  164  180  219  21  39  141  219  1592  197  53  59  127  197  240  0  48  102  240  1594  194   63   104  158  182  246  6  54  138  168  1604   168  69  84  123  147  282  33  63  135  222  1606  174  39 In order to determine whether or not phenoxybenzamine might act upon autonomic ganglia or postganglionic sympathetic nerves, ganglionic blockade was induced by hexamethonium before phenoxybenzamine was administered. Atropine was also given since autonomic ganglia contain cholinoceptive sites, some of which are stimulated by nicotine and some of which are muscarinic receptors (10, 23) . The cardiac output and heart rate increase after phenoxybenzamine was delayed until the 10 min period and was significantly less than without ganglionic blockade. Neither heart rate nor cardiac output exceeded the values preceding ganglionic blockade, which of itself tended to decrease heart rate and cardiac output. The minor cardiac effects of phenoxybenzamine after ganglionic blockade might result from circulating catecholamines, stimulation of postganglionic sympathetic nerve endings, or antivagal effects. In our studies, however, antivagal effects should have been already maximal because of the administration of atropine, 1 mg/kg before phenoxybenzamine. The immediate fall and later rise in blood pressure after phenoxybenzamine in animals undergoing ganglionic blockade was also observed by Benfey (24) . He was uncertain of the mechanism but speculated that the effect might result from catecholamine release, since atropine and ganglionic blocking drugs potentiate the hypertensive effects of norepinephrine.
Peripheral vagal stimulation frequency response curves showed evidence of antivagal action after phenoxybenzamine in each of our animals studied. Tachycardia induced by isoproterenol infusion did not impair the cardiac slowing induced by vagal stimulation. Hence the diminished response of the heart rate to vagal stimulation after phenoxybenzamine should not have been a nonspecific effect of tachycardia. Benfey (25) found no effect of phenoxybenzamine, 10 mg/kg, upon the negative chronotropic action of vagal stimulation or methacholine injection. His experiments differed from ours in that pentobarbitone anesthesia was used and his animals might have had lower vagal tone initially (26) . A more recent study has described a vagal blocking action of phenoxybenzamine as determined by direct perfusion of the sinoatrial node (27) .
Our studies show clearly that beta adrenergic receptor blockade prevented increased cardiac rate and cardiac output after phenoxybenzamine. This observation appears to indicate that the antivagal effects of phenoxybenzamine do not play a major part in the tachycardia observed after its administration. There is some question as to whether or not an antivagal effect can increase the heart rate in the absence of beta adrenergic cardiac nerve function. Vagal section was found to cause little cardiac acceleration in dogs when cardiac sympathectomy had been performed after vagotomy (28) . For this reason, we studied four dogs with beta receptor blockade produced by sotalol, 5 mg/kg intravenously. Bilateral cervical vagotomy increased the heart rates from 93 to 133 and from 50 to 102 beats/min, respectively, in two dogs. In the other two, after atropine, 0.2 mg/kg intravenously, the heart rates rose from 108 to 135 and from 63 to 198 beats/min, respectively. Thus, if phenoxybenzamine's antivagal action had a major responsibility for increasing the heart rate, it should have been demonstrable after beta adrenergic receptor blockade in our experiments.
Baroreceptor denervation effectively prevented an increase of cardiac output after phenoxybenzamine thus supporting the concept that the increase of heart rate and cardiac output are reflexly mediated by effects upon the carotid and aortic baroreceptors. Even though baroreceptors may exist in the common carotid arteries of cats (29), they did not seem effective in mediating an increase of cardiac output in our animals. We could not evaluate the role of the baroreceptors in increasing the heart rate after phenoxybenzamine, since the vagal section necessary for aortic arch denervation produced a nearly maximum heart rate before phenoxybenzamine was given. Since the changes in cardiac output did not correlate temporally with changes in blood catecholamine levels, it is possible that the baroreceptor effects of phenoxybenzamine are mediated neurogenically rather than humorally. It is concluded that phenoxybenzamine increases the heart rate and cardiac output principally by decreasing the systemic blood pressure, thus decreasing stimulation of receptors in the carotid sinus and aortic arch, which in turn act upon the heart through sympathetic nerves or circulating catecholamines.
